AXIM Biotechnologies (OTCMKTS:AXIM – Get Rating) is one of 440 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare AXIM Biotechnologies to similar businesses based on the strength of its earnings, profitability, risk, valuation, institutional ownership, dividends and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for AXIM Biotechnologies and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AXIM Biotechnologies | 0 | 0 | 0 | 0 | N/A |
| AXIM Biotechnologies Competitors | 916 | 2400 | 7408 | 86 | 2.62 |
As a group, “Biotechnology” companies have a potential upside of 131.15%. Given AXIM Biotechnologies’ competitors higher possible upside, analysts plainly believe AXIM Biotechnologies has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
Earnings and Valuation
This table compares AXIM Biotechnologies and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| AXIM Biotechnologies | N/A | N/A | -4.25 |
| AXIM Biotechnologies Competitors | $337.70 million | $40.71 million | -3.55 |
AXIM Biotechnologies’ competitors have higher revenue and earnings than AXIM Biotechnologies. AXIM Biotechnologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares AXIM Biotechnologies and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AXIM Biotechnologies | N/A | N/A | N/A |
| AXIM Biotechnologies Competitors | -1,071.94% | -86.67% | -28.49% |
Summary
AXIM Biotechnologies competitors beat AXIM Biotechnologies on 5 of the 8 factors compared.
About AXIM Biotechnologies
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Receive News & Ratings for AXIM Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AXIM Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
